With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in...

Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm New Data Reinforce KYPROLIS® (carfilzomib) as an...

INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline that was also much larger than a control saline injection A single...

Presentations focus on multiple myeloma including longitudinal study of response to anti-BCMA CAR-T therapy TAMPA, Fla., Dec. 8, 2023 /PRNewswire/ -- Aster Insights, the leading provider of...

Exults Digital Marketing is excited to exhibit at the 5th Annual Roofing Process Conference to showcase their online marketing services. ORLANDO, Fla., Dec. 8, 2023 /PRNewswire-PRWeb/ -- Exults...